Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

"We are excited to collaborate with PHC to unlock new possibilities in cell culture,” explained Michael May, President and ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

Mal-ID – can decipher an individual’s immune system’s record of past infections and diseases, according to a new study, providing a powerful tool with the potential for diagnosing autoimmune disorders ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Zilovertamab vedotin is currently being evaluated in the Phase 2/3 waveLINE-003 dose confirmation and expansion trial (NCT05139017 ... About diffuse large B-cell lymphoma Lymphoma is cancer ...

Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues ...

This new distribution center underscores our commitment to delivering high-quality functional antibodies to researchers ...